Last reviewed · How we verify

Isoflurane, Sevoflurane or Desflurane

King's College Hospital NHS Trust · FDA-approved active Small molecule

These volatile anesthetics enhance inhibitory GABA receptor signaling and inhibit excitatory NMDA receptor function to produce general anesthesia.

These volatile anesthetics enhance inhibitory GABA receptor signaling and inhibit excitatory NMDA receptor function to produce general anesthesia. Used for General anesthesia for surgical procedures, Maintenance of anesthesia during surgery.

At a glance

Generic nameIsoflurane, Sevoflurane or Desflurane
SponsorKing's College Hospital NHS Trust
Drug classVolatile anesthetic
TargetGABA-A receptor, NMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Isoflurane, sevoflurane, and desflurane are halogenated volatile anesthetics that work primarily by potentiating GABAergic neurotransmission in the central nervous system, thereby increasing inhibitory signaling. They also antagonize NMDA glutamate receptors, reducing excitatory neurotransmission. Together, these mechanisms produce rapid onset of unconsciousness, analgesia, and muscle relaxation suitable for surgical anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: